Repligen Co. Forecasted to Earn Q2 2024 Earnings of $0.33 Per Share (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN) – Stock analysts at Leerink Partnrs upped their Q2 2024 earnings per share estimates for shares of Repligen in a note issued to investors on Wednesday, May 1st. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will post earnings per share of $0.33 for the quarter, up from their prior estimate of $0.31. The consensus estimate for Repligen’s current full-year earnings is $1.46 per share. Leerink Partnrs also issued estimates for Repligen’s Q3 2024 earnings at $0.40 EPS, Q4 2024 earnings at $0.46 EPS, FY2024 earnings at $1.48 EPS, Q1 2025 earnings at $0.44 EPS, Q2 2025 earnings at $0.51 EPS, Q4 2025 earnings at $0.58 EPS and FY2025 earnings at $2.05 EPS.

Other analysts have also issued reports about the stock. Stifel Nicolaus upped their price target on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. KeyCorp raised their price target on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Finally, JPMorgan Chase & Co. lowered their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $197.75.

Repligen Price Performance

RGEN stock opened at $167.05 on Friday. The firm has a market cap of $9.33 billion, a P/E ratio of 668.23, a P/E/G ratio of 5.44 and a beta of 1.03. The firm’s fifty day moving average is $180.81 and its 200 day moving average is $174.09. Repligen has a 52 week low of $110.45 and a 52 week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 6.35.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The business had revenue of $151.31 million for the quarter, compared to the consensus estimate of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The firm’s revenue was down 17.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.64 earnings per share.

Insiders Place Their Bets

In other news, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares in the company, valued at approximately $16,892,409.45. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now owns 24,260 shares in the company, valued at $4,699,889.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the transaction, the director now owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The disclosure for this sale can be found here. Insiders sold 25,597 shares of company stock worth $5,039,532 over the last three months. Company insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CWM LLC grew its stake in shares of Repligen by 19.9% in the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 60 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Repligen by 0.3% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,178 shares of the biotechnology company’s stock valued at $3,805,000 after purchasing an additional 62 shares in the last quarter. abrdn plc raised its holdings in Repligen by 1.4% in the fourth quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock worth $934,000 after buying an additional 71 shares during the last quarter. Commerce Bank raised its holdings in Repligen by 4.5% in the fourth quarter. Commerce Bank now owns 1,683 shares of the biotechnology company’s stock worth $303,000 after buying an additional 72 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its holdings in Repligen by 15.1% in the 4th quarter. Quadrant Capital Group LLC now owns 649 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 85 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.